Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1990 Jul 28;301(6745):205–210. doi: 10.1136/bmj.301.6745.205

Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension.

A H van den Meiracker 1, P J Admiraal 1, A J Man in 't Veld 1, F H Derkx 1, H J Ritsema van Eck 1, P Mulder 1, P van Brummelen 1, M A Schalekamp 1
PMCID: PMC1663555  PMID: 2203486

Abstract

OBJECTIVE--To investigate the effects of a novel specific renin inhibitor, RO 42-5892, with high affinity for human renin (Ki = 0.5 x 10(-9) mol/l), on plasma renin activity and angiotensin II concentration and on 24 hour ambulatory blood pressure in essential hypertension. DESIGN--Exploratory study in which active treatment was preceded by placebo. SETTING--Inpatient unit of teaching hospital. PATIENTS--Nine men with uncomplicated essential hypertension who had a normal sodium intake. INTERVENTIONS--Two single intravenous doses of RO 42-5892 (100 and 1,000 micrograms/kg in 10 minutes) given to six patients and one single oral dose (600 mg) given to the three others as well as to three of the patients who also received the two intravenous doses. RESULTS--With both intravenous and oral doses renin activity fell in 10 minutes to undetectably low values, while angiotensin II concentration fell overall by 80-90% with intravenous dosing and by 30-40% after the oral dose. Angiotensin II concentration was back to baseline four hours after the low and six hours after the high intravenous dose and remained low for at least eight hours after the oral dose. Blood pressure fell rapidly both after low and high intravenous doses and after the oral dose and remained low for hours. With the high intravenous dose the daytime (0900-2230), night time (2300-0600), and next morning (0630-0830) systolic blood pressures were significantly (p less than 0.05) lowered by 12.5 (95% confidence interval 5.6 to 19.7), 12.2 (5.4 to 19.3), and 10.7 (3.2 to 18.5) mm Hg respectively, and daytime diastolic pressure was lowered by 9.3 (2.2 to 16.8) mmHg. With the oral dose daytime, night time, and next morning systolic blood pressures were lowered by 10.3 (5.5 to 15.4), 10.5 (4.2 to 17.2), and 9.7 (4.0 to 15.6) mm Hg, and daytime and night time diastolic pressures were lowered by 5.8 (0.9 to 11.0) and 6.0 (0.3-12) mm Hg respectively. CONCLUSIONS--The effect of the inhibitor on blood pressure was maintained over a longer period than its effect on angiotensin II. RO 42-5892 is orally active and has a prolonged antihypertensive effect in patients who did not have sodium depletion. This prolonged effect seems to be independent, at least in part, of the suppression of circulating angiotensin II.

Full text

PDF
205

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Admiraal P. J., Derkx F. H., Danser A. H., Pieterman H., Schalekamp M. A. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension. 1990 Jan;15(1):44–55. doi: 10.1161/01.hyp.15.1.44. [DOI] [PubMed] [Google Scholar]
  2. Bund S. J., Aalkjaer C., Heagerty A. M., Leckie B., Lever A. F. The contractile effects of porcine tetradecapeptide renin substrate in human resistance vessels: evidence of activation by vascular wall renin and serine proteases. J Hypertens. 1989 Sep;7(9):741–746. [PubMed] [Google Scholar]
  3. Delabays A., Nussberger J., Porchet M., Waeber B., Hoyos P., Boger R., Glassman H., Kleinert H. D., Luther R., Brunner H. R. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension. 1989 Jun;13(6 Pt 2):941–947. doi: 10.1161/01.hyp.13.6.941. [DOI] [PubMed] [Google Scholar]
  4. Derkx F. H., Tan-Tjiong L., Wenting G. J., Boomsma F., Man in 't Veld A. J., Schalekamp M. A. Asynchronous changes in prorenin and renin secretion after captopril in patients with renal artery stenosis. Hypertension. 1983 Mar-Apr;5(2):244–256. doi: 10.1161/01.hyp.5.2.244. [DOI] [PubMed] [Google Scholar]
  5. Dzau V. J. Significance of the vascular renin-angiotensin pathway. Hypertension. 1986 Jul;8(7):553–559. doi: 10.1161/01.hyp.8.7.553. [DOI] [PubMed] [Google Scholar]
  6. Kifor I., Dzau V. J. Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensins. Circ Res. 1987 Mar;60(3):422–428. doi: 10.1161/01.res.60.3.422. [DOI] [PubMed] [Google Scholar]
  7. Kleinert H. D., Martin D., Chekal M., Young G., Rosenberg S., Plattner J. J., Perun T. J. Cardiovascular actions of the primate-selective renin inhibitor, A-62198. J Pharmacol Exp Ther. 1988 Sep;246(3):975–979. [PubMed] [Google Scholar]
  8. Mann S., Craig M. W., Balasubramanian V., Cashman P. M., Raftery E. B. Ambulant blood pressure: reproducibility and the assessment of interventions. Clin Sci (Lond) 1980 Dec;59(6):497–500. doi: 10.1042/cs0590497. [DOI] [PubMed] [Google Scholar]
  9. Nussberger J., Delabays A., De Gasparo M., Cumin F., Waeber B., Brunner H. R., Ménard J. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers. Hypertension. 1989 Jun;13(6 Pt 2):948–953. doi: 10.1161/01.hyp.13.6.948. [DOI] [PubMed] [Google Scholar]
  10. Oliver J. A., Sciacca R. R. Local generation of angiotensin II as a mechanism of regulation of peripheral vascular tone in the rat. J Clin Invest. 1984 Oct;74(4):1247–1251. doi: 10.1172/JCI111534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pals D. T., Thaisrivongs S., Lawson J. A., Kati W. M., Turner S. R., DeGraaf G. L., Harris D. W., Johnson G. A. An orally active inhibitor of renin. Hypertension. 1986 Dec;8(12):1105–1112. doi: 10.1161/01.hyp.8.12.1105. [DOI] [PubMed] [Google Scholar]
  12. Saito H., Nakamaru M., Ogihara T., Rakugi H., Kumahara Y., Shimamoto K., Miyazaki M., Inagami T. Renin inhibitor and converting enzyme inhibitors suppress vascular angiotensin II. Hypertension. 1989 Jun;13(6 Pt 2):749–753. doi: 10.1161/01.hyp.13.6.749. [DOI] [PubMed] [Google Scholar]
  13. Verburg K. M., Kleinert H. D., Kadam J. R., Chekal M. A., Mento P. F., Wilkes B. M. Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys. Hypertension. 1989 Mar;13(3):262–272. doi: 10.1161/01.hyp.13.3.262. [DOI] [PubMed] [Google Scholar]
  14. Webb D. J., Manhem P. J., Ball S. G., Inglis G., Leckie B. J., Lever A. F., Morton J. J., Robertson J. I., Murray G. D., Ménard J. A study of the renin inhibitor H142 in man. J Hypertens. 1985 Dec;3(6):653–658. doi: 10.1097/00004872-198512000-00013. [DOI] [PubMed] [Google Scholar]
  15. Wood J. M., Gulati N., Forgiarini P., Fuhrer W., Hofbauer K. G. Effects of a specific and long-acting renin inhibitor in the marmoset. Hypertension. 1985 Sep-Oct;7(5):797–803. doi: 10.1161/01.hyp.7.5.797. [DOI] [PubMed] [Google Scholar]
  16. Zusman R. M., Burton J., Christensen D., Nussberger J., Dodds A., Haber E. Hemodynamic effects of a competitive renin inhibitory peptide in humans: evidence for multiple mechanisms of action. Trans Assoc Am Physicians. 1983;96:365–374. [PubMed] [Google Scholar]
  17. de Gasparo M., Cumin F., Nussberger J., Guyenne T. T., Wood J. M., Menard J. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol. 1989 May;27(5):587–596. doi: 10.1111/j.1365-2125.1989.tb03421.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. van den Meiracker A. H., Man in 't Veld A. J., van Eck H. J., Boomsma F., Schalekamp M. A. Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol, and propranolol in hypertensive patients. Circulation. 1988 Oct;78(4):957–968. doi: 10.1161/01.cir.78.4.957. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES